Brand Medications with Generic Alternatives Anticipated to be Approved in April

April 1, 2022

  • Zoladex (goserelin implant) – for prostate cancer, breast cancer, and endometriosis

Adverse reactions or quality problems experienced with the use of a recalled product can be reported to the FDA’s MedWatch Adverse Event Reporting Program online, by mail, or by fax.

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager